Trial reportNutrients2015
Lipid extract from hard-shelled mussel (Mytilus coruscus) improves clinical conditions of patients with rheumatoid arthritis: a randomized controlled trial.
Trial report in Nutrients, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02173587 (Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis), which is not on this map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- The Relationship between Fatty Acids and the Development, Course and Treatment of Rheumatoid Arthritis.Nutrients · 2022Pooled it
- Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials.Nutrients · 2017Pooled it
- Influence of Blue Mussel (Nutrients · 2018Trial
- Review
- Methanol extract of Chenopodium murale L. attenuated TNF-α-mediated oxidative stress and inflammation in murine models.Inflammopharmacology · 2026Article
- Therapeutic Effect and Underlying Mechanism of Blue Mussel (Nutrients · 2026Article
- Immunomodulatory Compounds from the Sea: From the Origins to a Modern Marine Pharmacopoeia.Marine drugs · 2024Review
- Free Fatty Acid 4 Receptor Activation Attenuates Collagen-Induced Arthritis by Rebalancing Th1/Th17 and Treg Cells.International journal of molecular sciences · 2024Article
- Mussel oil is superior to fish oil in preventing atherosclerosis of ApoEFrontiers in nutrition · 2024Article
- Association between fish intake and prevalence of frailty in community-dwelling older adults after 4-year follow-up: the Korean frailty and aging cohort study.Frontiers in nutrition · 2023Article
- Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus 2.0.International journal of molecular sciences · 2022Review
- Anticancer Potential of Lipophilic Constituents of Eleven Shellfish Species Commonly Consumed in Korea.Antioxidants (Basel, Switzerland) · 2021Article
- The Whole-Genome Sequencing and Hybrid Assembly ofFrontiers in genetics · 2020Article
- Uncommon Fatty Acids and Cardiometabolic Health.Nutrients · 2018Review
- Protective Effects of a Lipid Extract from Hard-Shelled Mussel (Nutrients · 2018Article
- Mussel (Mytilus coruscus) Water Extract Containing Taurine Prevents LPS-Induced Inflammatory Responses in Zebrafish Model.Advances in experimental medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have suggested a lipid extract from hard-shelled mussel (Mytilus coruscus) (HMLE) possessed strong anti-inflammatory activity in arthritis model of rats. This study investigated whether HMLE could improve clinical conditions of rheumatoid arthritis patients. Fifty rheumatoid arthritis patients (28-75 years) were randomly assigned to receive HMLE capsules or receive placebo capsules for 6 months. Forty-two subjects and 50 subjects were included in per-protocol and intention-to-treat analysis, respectively. Significant differences in changes on disease activity score (DAS28) and clinical disease activity index (CDAI) after 6-month intervention (p < 0.01) were observed in both analyses with more evident efficacy shown in per-protocol population (∆DAS28 = 0.47; ∆CDAI = 4.17), which favored the benefits of the HMLE group. TNF-α (tumor necrosis factor α), interleukin (IL)-1β and PGE2 (prostaglandin E2) but not IL-6, were significantly decreased in both groups, and the decrements were much larger in the HMLE group for TNF-α and PGE2 after 6 months from baseline (p < 0.05). IL-10 was significantly increased in both groups and the change was much more evident in the HMLE group (p < 0.05). In conclusion, HMLE exhibited benefits for the clinical conditions of rheumatoid patients in relation to improvement in the balance between pro- and anti-inflammatory factors, which indicated its potential to serve as adjunctive treatment for rheumatoid arthritis. (ClinicalTrials.gov NCT02173587).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.